Nils Kruse, Katrin Neumann, Arnhild Schrage, Katja Derkow, Eckart Schott, Ulrike Erben, Anja Kühl, Christoph Loddenkemper, Martin Zeitz, Alf Hamann, Katja Klugewitz – 20 November 2009 – Elucidating cellular mechanisms that maintain the intrahepatic immune balance is crucial to our understanding of viral or autoimmune liver diseases and allograft acceptance.

John J. Vargo, Lawrence B. Cohen, Douglas K. Rex, Paul Y. Kwo – 20 November 2009

Eiji Kakazu, Yoshiyuki Ueno, Yasuteru Kondo, Koji Fukushima, Masaaki Shiina, Jun Inoue, Keiichi Tamai, Masashi Ninomiya, Tooru Shimosegawa – 20 November 2009 – An imbalance of plasma amino acids is observed in patients with advanced cirrhosis. The aim of this study was to investigate the influence of the extracellular amino acid imbalance on the function of myeloid dendritic cells (DCs) in patients with advanced cirrhosis.

Sander S. Rensen, Yanti Slaats, Ann Driessen, Carine J. Peutz‐Kootstra, Jeroen Nijhuis, Rudi Steffensen, Jan Willem Greve, Wim A. Buurman – 20 November 2009 – Activation of the innate immune system plays a major role in nonalcoholic fatty liver disease (NAFLD). The complement system is an important component of innate immunity that recognizes danger signals such as tissue injury.

Delphine Garnier, Pascal Loyer, Catherine Ribault, Christiane Guguen‐Guillouzo, Anne Corlu – 20 November 2009 – Liver regeneration is a unique process to restore hepatic homeostasis through rapid and synchronous proliferation of differentiated hepatocytes. Previous studies have shown that hepatocyte proliferation is characterized by high expression levels of the “mitotic” cyclin‐dependent kinase 1 (Cdk1) during S‐phase compared to other mammalian cells.

Michael L. Volk, Rachel Tocco, Sameer Saini, Anna S.F. Lok – 20 November 2009 – Despite dramatic improvements in antiviral therapy for hepatitis C, there is reason to believe that the uptake of antiviral therapy remains limited. The aims of this study were to determine the number of patients being treated with antiviral therapy in the U.S., to estimate the public health impact of these treatment patterns, and to identify barriers to treatment for patients with hepatitis C.

Manuel Romero‐Gómez, Moisés Diago, Raúl J. Andrade, José L. Calleja, Javier Salmerón, Conrado M. Fernández‐Rodríguez, Ricard Solà, Javier García‐Samaniego, Juan M. Herrerías, Manuel De la Mata, Ricardo Moreno‐Otero, Óscar Nuñez, Antonio Olveira, Santiago Durán, Ramón Planas, Spanish TRIC‐1 (Treatment of Resistance to Insulin in Hepatitis C Genotype 1) group – 20 November 2009 – Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C.

Horng‐Ren Yang, Hong‐Shuie Chou, Xiaodong Gu, Lianfu Wang, Kathleen E. Brown, John J. Fung, Lina Lu, Shiguang Qian – 20 November 2009 – The liver is considered to be an immune‐privileged organ that favors the induction of tolerance. The underlying mechanisms are not completely understood. Interestingly, liver transplants are spontaneously accepted in several animal models, but hepatocyte transplants are acutely rejected, suggesting that liver nonparenchymal cells may effectively protect the parenchymal cells from immune attack.

20 November 2009

Junfang Ji, Xin Wei Wang – 20 November 2009